Literature DB >> 15619231

Elevated endogenous GABA level correlates with decreased fMRI signals in the rat brain during acute inhibition of GABA transaminase.

Zhengguang Chen1, Afonso C Silva, Jehoon Yang, Jun Shen.   

Abstract

Vigabatrin and gabaculine, both highly specific inhibitors of GABA (gamma-aminobutyric acid) transaminase, cause significant elevation of endogenous GABA levels in brain. The time course of GABA concentration after acute GABA transaminase inhibition was measured quantitatively in the alpha-chloralose-anesthetized rat brain using in vivo selective homonuclear polarization transfer spectroscopy. The blood oxygenation level-dependent (BOLD) effect in functional magnetic resonance imaging (fMRI) has been considered to be coupled tightly to neuronal activation via the metabolic demand of associated glutamate transport. Correlated with the rise in endogenous GABA level after vigabatrin or gabaculine treatment, the intensity of BOLD-weighted fMRI signals in rat somatosensory cortex during forepaw stimulation was found to be reduced significantly. These results are consistent with previous findings that inhibition of GABA transaminase leads to augmented GABA release and potentiation of GABAergic inhibition.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15619231     DOI: 10.1002/jnr.20364

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  29 in total

Review 1.  Is there a path beyond BOLD? Molecular imaging of brain function.

Authors:  Alan P Koretsky
Journal:  Neuroimage       Date:  2012-03-03       Impact factor: 6.556

2.  Integrated RF probe for in vivo multinuclear spectroscopy and functional imaging of rat brain using an 11.7 Tesla 89 mm bore vertical microimager.

Authors:  S Li; J Shen
Journal:  MAGMA       Date:  2005-07-08       Impact factor: 2.310

Review 3.  The micro-architecture of the cerebral cortex: functional neuroimaging models and metabolism.

Authors:  Jorge J Riera; Arne Schousboe; Helle S Waagepetersen; Clare Howarth; Fahmeed Hyder
Journal:  Neuroimage       Date:  2008-01-11       Impact factor: 6.556

4.  Mechanical flutter stimulation induces a lasting response in the sensorimotor cortex as revealed with BOLD fMRI.

Authors:  Monica Christova; Stefan Golaszewski; Anja Ischebeck; Alexander Kunz; Dietmar Rafolt; Raffaele Nardone; Eugen Gallasch
Journal:  Hum Brain Mapp       Date:  2012-05-19       Impact factor: 5.038

5.  High-resolution BOLD fMRI measurements of local orientation-dependent contextual modulation show a mismatch between predicted V1 output and local BOLD response.

Authors:  Jennifer F Schumacher; Cheryl A Olman
Journal:  Vision Res       Date:  2010-04-09       Impact factor: 1.886

6.  Decreased cerebellar-cerebral connectivity contributes to complex task performance.

Authors:  Curren Katz; André Knops
Journal:  J Neurophysiol       Date:  2016-06-22       Impact factor: 2.714

7.  The effects of capillary transit time heterogeneity on the BOLD signal.

Authors:  Hugo Angleys; Sune N Jespersen; Leif Østergaard
Journal:  Hum Brain Mapp       Date:  2018-03-02       Impact factor: 5.038

Review 8.  Methodological considerations in rat brain BOLD contrast pharmacological MRI.

Authors:  C A Steward; C A Marsden; M J W Prior; P G Morris; Y B Shah
Journal:  Psychopharmacology (Berl)       Date:  2005-09-14       Impact factor: 4.530

9.  Zolpidem reduces the blood oxygen level-dependent signal during visual system stimulation.

Authors:  Stephanie C Licata; Steven B Lowen; George H Trksak; Robert R Maclean; Scott E Lukas
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-05-30       Impact factor: 5.067

10.  GABAA receptors predict aversion-related brain responses: an fMRI-PET investigation in healthy humans.

Authors:  Dave J Hayes; Niall W Duncan; Christine Wiebking; Karin Pietruska; Pengmin Qin; Stefan Lang; Jean Gagnon; Paul Gravel Bing; Jeroen Verhaeghe; Alexey P Kostikov; Ralf Schirrmacher; Andrew J Reader; Julien Doyon; Pierre Rainville; Georg Northoff
Journal:  Neuropsychopharmacology       Date:  2013-02-06       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.